Drugs / insulin degludec/liraglutide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02100475 | Apr 2014 → Apr 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | insulin degludec/liraglutide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02100475 ↗ |
| Route | Subcutaneous | “Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin.” NCT02100475 ↗ |